EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Inclusion Criteria for Observation Phase: * Voluntarily sign and date an informed consent agreement * Have participated in and completed the double-blind study EN3835-201 * Be willing to apply sunscreen to any treated quadrant before each exposure to sun Inclusion Criteria for Treatment Phase: * Voluntarily sign and date an informed consent agreement * Have participated in and completed the double-blind study EN3835-201 * Be willing to apply sunscreen to any treated quadrant before each exposure to sun * Have at least 1 quadrant with: a score of 3 or 4 (moderate or severe) as reported on the PCSS (Photonumeric Cellulite Severity Scale) by the subject or investigator, and a Hexsel CSS (Cellulite Severity Scale) score no greater than 13 * Be judged to be in good health * Have a negative urine pregnancy test at screening and be using an effective contraception method, be surgically sterile, or post-menopausal Exclusion Criteria for Observation Phase: * None Exclusion Criteria for Treatment Phase: * Has used, or intends to use during the course of the study, other treatment of EFP on the legs or buttocks * Is presently nursing a baby or providing breast milk for a baby * Intends to become pregnant during the study * Currently receiving, has received within 7 days before injection of study drug, or plans to receive an anticoagulant or antiplatelet medication * History of stroke or bleeding